Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 256 articles: HTML format

Single Articles

April 2024
1. OHAMA H, Hiraoka A, Tada T, Kariyama K, et al
   Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
   J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553.
   PubMed     Abstract available
   
   
   
2. CHAN WK, George J
   Metabolic fatty liver syndromes: where do we stand in 2024?
   J Gastroenterol Hepatol. 2024;39:613-614.
   PubMed    
   
   
   
3. PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al
   Clinical outcomes after transplantation of domino grafts or standard deceased donor livers: a systematic review and meta-analysis.
   J Gastroenterol Hepatol. 2024;39:620-629.
   PubMed     Abstract available
   
   
   March 2024
4. WANG X, Liu H, Wang Y, Wang P, et al
   Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
   J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
   PubMed     Abstract available
   
   
   
5. SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al
   Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
   J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532.
   PubMed     Abstract available
   
   
   
6. BALE G, Kulkarni AV, Padaki NR, Menon PB, et al
   Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty liver disease: a whole exome sequencing approach.
   J Gastroenterol Hepatol. 2024;39:587-595.
   PubMed     Abstract available
   
   
   February 2024
7. 
   Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
   J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
   PubMed    
   
   
   
8. TADA T, Kumada T, Hiraoka A, Kariyama K, et al
   mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
   J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512.
   PubMed     Abstract available
   
   
   
9. WANG J, Zhang Y, Ma Y, Zhao S, et al
   TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
   J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
   PubMed     Abstract available
   
   
   
10. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    PubMed     Abstract available
    
    
    
11. HAHN JW, Lee H, Shin M, Seong MW, et al
    Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia.
    J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505.
    PubMed     Abstract available
    
    
    
12. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    PubMed     Abstract available
    
    
    January 2024
13. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    PubMed     Abstract available
    
    
    
14. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    PubMed     Abstract available
    
    
    
15. DIAO L, Wang C, You R, Leng B, et al
    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463.
    PubMed     Abstract available
    
    
    
16. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    PubMed     Abstract available
    
    
    
17. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    PubMed     Abstract available
    
    
    
18. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
    J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483.
    PubMed     Abstract available
    
    
    December 2023
19. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    PubMed    
    
    
    
20. CHO SH, Song TJ, Oh D, Park DH, et al
    Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage for right intrahepatic duct dilatation in malignant hilar obstruction.
    J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442.
    PubMed     Abstract available
    
    
    
21. TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al
    Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441.
    PubMed     Abstract available
    
    
    
22. HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al
    Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic translation
    J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408.
    PubMed     Abstract available
    
    
    
23. YANG Y, Liu S, Li H, Liu Y, et al
    The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced acute alcoholic liver disease and gut microbiota disturbance in mice.
    J Gastroenterol Hepatol. 2023;38:2185-2194.
    PubMed     Abstract available
    
    
    
24. TONG C, Halengbieke A, Ni X, Han Y, et al
    Bidirectional relationship between nonalcoholic fatty liver disease and serum creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
    J Gastroenterol Hepatol. 2023;38:2061-2069.
    PubMed     Abstract available
    
    
    
25. NARANG M, Shah D, Narang S, Gupta N, et al
    Ultrasound-guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial.
    J Gastroenterol Hepatol. 2023;38:2070-2075.
    PubMed     Abstract available
    
    
    November 2023
26. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    PubMed     Abstract available
    
    
    
27. DU S, Cao K, Yan Y, Wang Y, et al
    Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416.
    PubMed     Abstract available
    
    
    
28. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    PubMed    
    
    
    
29. FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al
    Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome in alcoholic hepatitis without liver transplantation: a nationwide analysis.
    J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388.
    PubMed     Abstract available
    
    
    
30. SUN J
    Navigating the complex landscape of non-alcoholic fatty liver disease: From genomic associate to the AMPK/mTOR pathways.
    J Gastroenterol Hepatol. 2023;38:1863-1864.
    PubMed    
    
    
    
31. TIAN Y, Wang B
    Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
    J Gastroenterol Hepatol. 2023;38:1877-1885.
    PubMed     Abstract available
    
    
    
32. WANG Y, Huang Y, Zheng T, Sun C, et al
    Gastrointestinal hospitalization during COVID-19 pandemic in the United States: Analysis of a nationwide inpatient sample.
    J Gastroenterol Hepatol. 2023;38:1971-1979.
    PubMed     Abstract available
    
    
    
33. TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al
    Association between equol and non-alcoholic fatty liver disease in Japanese women in their 50s and 60s.
    J Gastroenterol Hepatol. 2023;38:1958-1962.
    PubMed     Abstract available
    
    
    
34. MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al
    AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    J Gastroenterol Hepatol. 2023;38:1868-1876.
    PubMed     Abstract available
    
    
    October 2023
35. QUAN Y, Shou D, Yang S, Cheng J, et al
    Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by inhibiting JNK/MFF signaling.
    J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372.
    PubMed     Abstract available
    
    
    
36. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    PubMed     Abstract available
    
    
    
37. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    PubMed    
    
    
    
38. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    PubMed     Abstract available
    
    
    
39. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    PubMed     Abstract available
    
    
    
40. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
    J Gastroenterol Hepatol. 2023;38:1823-1831.
    PubMed     Abstract available
    
    
    
41. RONG L, Ch'ng D, Jia P, Tsoi KKF, et al
    Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1682-1694.
    PubMed     Abstract available
    
    
    
42. TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al
    Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:1743-1749.
    PubMed     Abstract available
    
    
    September 2023
43. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    PubMed     Abstract available
    
    
    
44. HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al
    Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the cause of jaundice and liver failure.
    J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350.
    PubMed    
    
    
    
45. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    PubMed     Abstract available
    
    
    
46. MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al
    Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
    J Gastroenterol Hepatol. 2023;38:1637-1646.
    PubMed     Abstract available
    
    
    
47. HAN E, Chun HS, Lee YH, Lee JS, et al
    MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    J Gastroenterol Hepatol. 2023;38:1598-1609.
    PubMed     Abstract available
    
    
    August 2023
48. HAYASHI H, Sawada K, Tanaka H, Muro K, et al
    The effect of heat-killed Lactobacillus brevis SBL88 on improving selective hepatic insulin resistance in non-alcoholic fatty liver disease mice without altering the gut microbiota.
    J Gastroenterol Hepatol. 2023 Aug 30. doi: 10.1111/jgh.16337.
    PubMed     Abstract available
    
    
    
49. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    PubMed     Abstract available
    
    
    
50. ANIRVAN P
    Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
    PubMed    
    
    
    
51. KIM K, Lee HW, Ahn SH
    How can we improve surveillance system for alcohol-associated hepatocellular carcinoma?
    J Gastroenterol Hepatol. 2023;38:1203-1204.
    PubMed    
    
    
    
52. CHEN M, Zhong W, Xu W
    Alcohol and the mechanisms of liver disease.
    J Gastroenterol Hepatol. 2023;38:1233-1240.
    PubMed     Abstract available
    
    
    
53. ZHANG LY, Wang CY, Xu Q, Mu ZQ, et al
    Removal of epigenetic repressive mark on inflammatory genes in fat liver.
    J Gastroenterol Hepatol. 2023;38:1426-1437.
    PubMed     Abstract available
    
    
    
54. JACOB R, Prince DS, Kench C, Liu K, et al
    Alcohol and its associated liver carcinogenesis.
    J Gastroenterol Hepatol. 2023;38:1211-1217.
    PubMed     Abstract available
    
    
    
55. VIJAYALEKSHMI B, Choudhary A, Alexander V, Prabhu SB, et al
    Reticuloendothelial activation and phenotypic alteration of peripheral monocytes with enhanced liver recruitment drive liver injury secondary to yellow phosphorus.
    J Gastroenterol Hepatol. 2023;38:1408-1415.
    PubMed     Abstract available
    
    
    
56. LI R, Liu J, Han P, Shi R, et al
    Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
    J Gastroenterol Hepatol. 2023;38:1316-1324.
    PubMed     Abstract available
    
    
    
57. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
    Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
    J Gastroenterol Hepatol. 2023;38:1325-1332.
    PubMed     Abstract available
    
    
    
58. JEW MH, Hsu CL
    Alcohol, the gut microbiome, and liver disease.
    J Gastroenterol Hepatol. 2023;38:1205-1210.
    PubMed     Abstract available
    
    
    July 2023
59. CHO MS, Lee SK, Kwon JH, Nam SW, et al
    Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
    J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
    PubMed    
    
    
    
60. CHOI WM, Yoo SY, Chang JI, Han S, et al
    A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
    J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
    PubMed     Abstract available
    
    
    
61. LIU X, Wang J, Li M, Qiu J, et al
    Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
    J Gastroenterol Hepatol. 2023 Jul 6. doi: 10.1111/jgh.16279.
    PubMed     Abstract available
    
    
    
62. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
    How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
    PubMed     Abstract available
    
    
    
63. CHENG HY, Hu RH, Hsiao CY, Ho MC, et al
    Hepatitis C treatment and long-term outcome of patients with hepatocellular carcinoma after resection.
    J Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1111/jgh.16276.
    PubMed     Abstract available
    
    
    
64. LIU M, Qiu H, Zhang W, Mei T, et al
    Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1018-1027.
    PubMed     Abstract available
    
    
    
65. LIU P, Yao L, Hu X, Wang Z, et al
    Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases.
    J Gastroenterol Hepatol. 2023;38:1099-1106.
    PubMed     Abstract available
    
    
    
66. SHEN J, Cao J, Chen M, Zhang Y, et al
    Recent advances in the role of exosomes in liver fibrosis.
    J Gastroenterol Hepatol. 2023;38:1083-1088.
    PubMed     Abstract available
    
    
    
67. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
    A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
    J Gastroenterol Hepatol. 2023;38:1148-1157.
    PubMed     Abstract available
    
    
    
68. JIANG N, Xiao Y, Yuan K, Wang Z, et al
    Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    J Gastroenterol Hepatol. 2023;38:1056-1071.
    PubMed     Abstract available
    
    
    June 2023
69. MINORETTI P, Emanuele E
    Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
    PubMed    
    
    
    
70. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
    Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
    PubMed     Abstract available
    
    
    
71. GIRI S, Singh A, Kolhe K, Kale A, et al
    Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
    PubMed     Abstract available
    
    
    
72. LIU J, Man K
    Biomarkers for monitoring alcohol sobriety after liver transplantation for alcoholic liver disease.
    J Gastroenterol Hepatol. 2023 Jun 23. doi: 10.1111/jgh.16269.
    PubMed     Abstract available
    
    
    
73. SUZUKI Y, Maekawa S, Yamashita K, Osawa L, et al
    Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:921-929.
    PubMed     Abstract available
    
    
    
74. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
    Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    J Gastroenterol Hepatol. 2023;38:896-904.
    PubMed     Abstract available
    
    
    May 2023
75. TADA T, Kumada T, Hiraoka A, Hirooka M, et al
    Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 May 25. doi: 10.1111/jgh.16225.
    PubMed     Abstract available
    
    
    
76. DONG Y, Liu Y, Liu X, Ma H, et al
    Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
    J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
    PubMed     Abstract available
    
    
    
77. WU CW, Wong GL, Wong VW, Yam TF, et al
    Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
    J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
    PubMed     Abstract available
    
    
    
78. ZHOU F, Mai T, Wang Z, Zeng Z, et al
    The improvement of intestinal dysbiosis and hepatic metabolic dysfunction in dextran sulfate sodium-induced colitis mice: effects of curcumin.
    J Gastroenterol Hepatol. 2023 May 20. doi: 10.1111/jgh.16205.
    PubMed     Abstract available
    
    
    
79. KIM DS, Kim BK, Lee JS, Lee HW, et al
    Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
    J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
    PubMed     Abstract available
    
    
    
80. AHMED Z, Badal J, Nawras M, Battepati D, et al
    Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:703-709.
    PubMed     Abstract available
    
    
    
81. SHIRAKAMI Y, Kato J, Maeda T, Ideta T, et al
    Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-alpha in senescence-accelerated mice.
    J Gastroenterol Hepatol. 2023;38:800-808.
    PubMed     Abstract available
    
    
    April 2023
82. VERMA N, Vojjala N, Mishra S, Valsan A, et al
    Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
    J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
    PubMed     Abstract available
    
    
    
83. ALABBAS SY, Giri R, Oancea I, Davies J, et al
    Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver.
    J Gastroenterol Hepatol. 2023;38:609-618.
    PubMed     Abstract available
    
    
    March 2023
84. MURATA K, Mizokami M
    Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 14. doi: 10.1111/jgh.16178.
    PubMed     Abstract available
    
    
    
85. MAO S, Liu Q, Wu H, Zhu J, et al
    Phase separation of YAP mediated by CC domain promotes hepatoblastoma proliferation via activation of transcription.
    J Gastroenterol Hepatol. 2023 Mar 12. doi: 10.1111/jgh.16173.
    PubMed     Abstract available
    
    
    
86. MOU L, Li K, Xu C, Xu I, et al
    Construction of Endothelial Cell- and Autophagy-Related Prognostic Models for Hepatocellular Carcinoma Based on Single-Cell Data.
    J Gastroenterol Hepatol. 2023 Mar 9. doi: 10.1111/jgh.16172.
    PubMed     Abstract available
    
    
    
87. TSUMURA S, Shimose S, Niizeki T, Kuboyama E, et al
    Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
    J Gastroenterol Hepatol. 2023 Mar 7. doi: 10.1111/jgh.16168.
    PubMed     Abstract available
    
    
    
88. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
    PubMed     Abstract available
    
    
    
89. BOUSTANY A, Onwuzo S, Zeid HKA, Almomani A, et al
    Non-alcoholic steatohepatitis is independently associated with a history of gestational diabetes mellitus.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16163.
    PubMed     Abstract available
    
    
    
90. WONG GL
    Editorial: Appraising liver fibrosis with eagle eyes.
    J Gastroenterol Hepatol. 2023;38:343.
    PubMed    
    
    
    
91. CHEN Q, Guo J, Qiu T, Zhou J, et al
    Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: A critical pathway molecule worth investigating.
    J Gastroenterol Hepatol. 2023;38:378-385.
    PubMed     Abstract available
    
    
    
92. ZHAO Q, Liang L, Zhai F, Ling G, et al
    A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
    J Gastroenterol Hepatol. 2023;38:359-369.
    PubMed     Abstract available
    
    
    February 2023
93. DUNNE CL, Kaur S, Delacruz B, Bresee LC, et al
    30-day Readmission Rates Among Upper Gastrointestinal Bleeds: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2023 Feb 20. doi: 10.1111/jgh.16153.
    PubMed     Abstract available
    
    
    
94. ZHAO X, Shi X, Gu H, Zhou W, et al
    Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
    J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
    PubMed     Abstract available
    
    
    
95. MORAN-RAMOS S, Cerqueda-Garcia D, Lopez-Contreras B, Larrieta-Carrasco E, et al
    A metagenomic study identifies a Prevotella-copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity.
    J Gastroenterol Hepatol. 2023 Feb 17. doi: 10.1111/jgh.16147.
    PubMed     Abstract available
    
    
    
96. AAMANN L, Dam G, Jepsen P, Borre M, et al
    Reduced three-year risk of hospital admission and mortality after 12-weeks resistance training of cirrhosis patients - a follow-up of a randomized clinical trial.
    J Gastroenterol Hepatol. 2023 Feb 5. doi: 10.1111/jgh.16141.
    PubMed     Abstract available
    
    
    
97. NOGAMI A, Iwaki M, Kobayashi T, Honda Y, et al
    Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study.
    J Gastroenterol Hepatol. 2023;38:321-329.
    PubMed     Abstract available
    
    
    
98. MOHR I, Bourhis H, Woimant F, Obadia MA, et al
    Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
    J Gastroenterol Hepatol. 2023;38:219-224.
    PubMed     Abstract available
    
    
    January 2023
99. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    PubMed     Abstract available
    
    
    
100. LEE HA, Lee YS, Jung YK, Kim JH, et al
     Antiviral therapy does not improve outcomes of patients with HBV-related decompensated cirrhosis and undetectable DNA.
     J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16132.
     PubMed     Abstract available
     
     
     
101. BHATEJA A, Bodh V, Chauhan A
     Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
     J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
     PubMed     Abstract available
     
     
     
102. ZHANG Q, Jia R, Chen M, Wang J, et al
     Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
     J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
     PubMed     Abstract available
     
     
     
103. JANG W, Lee HW
     Hepatobiliary and Pancreatic: Hepatic mass discovered incidentally with telangiectasia.
     J Gastroenterol Hepatol. 2023 Jan 17. doi: 10.1111/jgh.16094.
     PubMed    
     
     
     
104. ABASSERI M, Hoque S, Kochovska S, Caldwell K, et al
     Barriers to Palliative Care in Hepatocellular Carcinoma: A Review of the Literature.
     J Gastroenterol Hepatol. 2023 Jan 12. doi: 10.1111/jgh.16107.
     PubMed     Abstract available
     
     
     December 2022
105. KAZANKOV K, Nixon-Hill M, Kumar R, Amin A, et al
     A novel Smartphone scleral-image based tool for assessing jaundice in decompensated cirrhosis patients.
     J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16093.
     PubMed     Abstract available
     
     
     
106. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
     Medical Management of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group.
     J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16097.
     PubMed     Abstract available
     
     
     
107. AHUJA H, Sharma BC, Sachdeva S, Mahajan B, et al
     A double blind Randomized Controlled Trial to assess efficacy of Nutritional Therapy for prevention of recurrence of Hepatic Encephalopathy in patients with Cirrhosis.
     J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16096.
     PubMed     Abstract available
     
     
     
108. LONG Y, Song X, Guan Y, Lan R, et al
     Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2022 Dec 14. doi: 10.1111/jgh.16088.
     PubMed     Abstract available
     
     
     
109. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
     Management and Monitoring of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical M
     J Gastroenterol Hepatol. 2022 Dec 12. doi: 10.1111/jgh.16084.
     PubMed     Abstract available
     
     
     
110. YOSHIDA S, Minaga K, Watanabe T, Kudo M, et al
     Hepatobiliary and Pancreatic: Multiple pancreatic masses with rich vascularity.
     J Gastroenterol Hepatol. 2022 Dec 5. doi: 10.1111/jgh.16060.
     PubMed    
     
     
     
111. SEKO Y, Kawanaka M, Fujii H, Iwaki M, et al
     Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
     J Gastroenterol Hepatol. 2022;37:2313-2320.
     PubMed     Abstract available
     
     
     November 2022
112. KARAGIANNAKIS DS, Voulgaris T, Markakis G, Lakiotaki D, et al
     Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis.
     J Gastroenterol Hepatol. 2022 Nov 8. doi: 10.1111/jgh.16057.
     PubMed     Abstract available
     
     
     
113. OUYANG R, Li H, Tan W, Wang X, et al
     Portal vein thrombosis compromises the performance of MELD and MELD-Na scores in patients with cirrhosis.
     J Gastroenterol Hepatol. 2022 Nov 7. doi: 10.1111/jgh.16053.
     PubMed     Abstract available
     
     
     
114. ALMOMANI A, Kumar P, Onwuzo S, Boustany A, et al
     Epidemiology and Prevalence of Lean Non-Alcoholic Fatty Liver Disease and Associated Cirrhosis, HCC and Cardiovascular Outcomes in the United States: A Population-Based Study and Review of Literature.
     J Gastroenterol Hepatol. 2022 Nov 3. doi: 10.1111/jgh.16049.
     PubMed     Abstract available
     
     
     
115. HAKODA H, Kiritani S, Kokudo T, Yoshimura K, et al
     Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
     J Gastroenterol Hepatol. 2022;37:2182-2188.
     PubMed     Abstract available
     
     
     October 2022
116. YANG Z, Wan W, Zhang P, Wang S, et al
     Crosstalk between heat shock factor 1 and signal transducer and activator of transcription 3 mediated by interleukin-8 autocrine signaling maintains the cancer stem cell phenotype in liver cancer.
     J Gastroenterol Hepatol. 2022 Oct 27. doi: 10.1111/jgh.16040.
     PubMed     Abstract available
     
     
     
117. GORGANI F, Esfahani Z, Ghamari SH, Ghasemi E, et al
     Global, Regional, and National Burden and Quality of Care Index of Liver Cirrhosis by Cause from Global Burden of Disease 1990-2019.
     J Gastroenterol Hepatol. 2022 Oct 26. doi: 10.1111/jgh.16041.
     PubMed     Abstract available
     
     
     
118. MEENA BL, Taneja S, Tandon P, Sahni N, et al
     Home-based Intensive Nutrition Therapy improves Frailty and Sarcopenia in Patients with Decompensated Cirrhosis: A Randomized Clinical Trial.
     J Gastroenterol Hepatol. 2022 Oct 21. doi: 10.1111/jgh.16035.
     PubMed     Abstract available
     
     
     
119. LIU Y, Chen M
     Targeting hepatic stellate cells may serve as a promising target for hepatic steatosis.
     J Gastroenterol Hepatol. 2022 Oct 18. doi: 10.1111/jgh.16028.
     PubMed    
     
     
     
120. SARAIVA RO, Gamelas V, Canha MI, Carvalho D, et al
     Hepatobiliary and Pancreatic: An unusual cause of biliary obstruction.
     J Gastroenterol Hepatol. 2022 Oct 10. doi: 10.1111/jgh.16009.
     PubMed    
     
     
     
121. HOU G, Xu W, Ding D, Tian T, et al
     Metabolome and Transcriptome Integration Reveals Metabolic Profile of Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2022 Oct 8. doi: 10.1111/jgh.16024.
     PubMed     Abstract available
     
     
     
122. FERNANDEZ M, Lokan J, Leung C, Grigg A, et al
     A critical evaluation of the role of iron overload in fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:1873-1883.
     PubMed     Abstract available
     
     
     
123. LIN CL, Tai CM, Huang JF, Liu CJ, et al
     The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
     J Gastroenterol Hepatol. 2022;37:1901-1910.
     PubMed     Abstract available
     
     
     
124. TONTIKIDOU C, Makri ES, Evripidou K, Goulis DG, et al
     Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.
     J Gastroenterol Hepatol. 2022;37:1853-1864.
     PubMed     Abstract available
     
     
     September 2022
125. ZHANG C, Dai D, Zhang W, Yang W, et al
     Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2022 Sep 6. doi: 10.1111/jgh.15999.
     PubMed     Abstract available
     
     
     
126. LIM SZ, Chuah KH, Rajaram RB, Stanley K, et al
     Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study.
     J Gastroenterol Hepatol. 2022;37:1732-1740.
     PubMed     Abstract available
     
     
     
127. JEE JJ, Lim J, Park S, Koh H, et al
     Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:1822-1832.
     PubMed     Abstract available
     
     
     
128. INADA K, Tamaki N, Kurosaki M, Kirino S, et al
     Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:1726-1731.
     PubMed     Abstract available
     
     
     August 2022
129. PRINCE DS, Schlaphoff G, Davison SA, Huo YR, et al
     Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study.
     J Gastroenterol Hepatol. 2022 Aug 28. doi: 10.1111/jgh.15986.
     PubMed     Abstract available
     
     
     
130. KAWAHARA A, Kanno K, Yonezawa S, Otani Y, et al
     Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
     J Gastroenterol Hepatol. 2022 Aug 6. doi: 10.1111/jgh.15974.
     PubMed     Abstract available
     
     
     
131. POHL K, Moodley P, Dhanda A
     The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review.
     J Gastroenterol Hepatol. 2022;37:1498-1506.
     PubMed     Abstract available
     
     
     
132. ZHANG H, Wang Y, Chen C, Wang B, et al
     Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes.
     J Gastroenterol Hepatol. 2022;37:1633-1640.
     PubMed     Abstract available
     
     
     
133. HA Y, Chon YE, Kim MN, Lee JH, et al
     Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:1624-1632.
     PubMed     Abstract available
     
     
     
134. KIM HJ, Park SJ, Park HK, Byun DW, et al
     Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study.
     J Gastroenterol Hepatol. 2022;37:1617-1623.
     PubMed     Abstract available
     
     
     July 2022
135. BINET Q, Annet L, Danse E, Goffette P, et al
     Hepatobiliary and Pancreatic: An uncommon cause of portal hypertension.
     J Gastroenterol Hepatol. 2022 Jul 28. doi: 10.1111/jgh.15961.
     PubMed    
     
     
     
136. LEE H, Kim BK
     Real-world clinical features, healthcare utilization, and economic burden in decompensated cirrhosis patients; a national database.
     J Gastroenterol Hepatol. 2022 Jul 21. doi: 10.1111/jgh.15962.
     PubMed     Abstract available
     
     
     
137. FENG G, He N, Xia HH, Mi M, et al
     Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15940.
     PubMed     Abstract available
     
     
     
138. UFUK F, Aykota MR
     Hepatobiliary and Pancreatic: Todani type I choledochal cyst and cystic malformation of the cystic duct.
     J Gastroenterol Hepatol. 2022 Jul 6. doi: 10.1111/jgh.15931.
     PubMed    
     
     
     
139. LONARDO A
     Precision medicine in nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:1175-1178.
     PubMed    
     
     
     
140. GIRI S, Agarwal D, Afzalpurkar S
     GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing.
     J Gastroenterol Hepatol. 2022;37:1406.
     PubMed    
     
     
     June 2022
141. KAKIZOE M, Nagata K, Sasaki R, Ozawa E, et al
     Hepatobiliary and Pancreatic: Ruptured pseudoaneurysm after endoscopic biliary stenting using the novel double-pit-type plastic stent.
     J Gastroenterol Hepatol. 2022 Jun 27. doi: 10.1111/jgh.15913.
     PubMed    
     
     
     
142. LIU J, Qian Y, Yang F, Huang S, et al
     Value of prediction-model in distinguishing gallbladder adenoma from cholesterol polyp.
     J Gastroenterol Hepatol. 2022 Jun 24. doi: 10.1111/jgh.15928.
     PubMed     Abstract available
     
     
     
143. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
     Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
     J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
     PubMed     Abstract available
     
     
     
144. WONG YJ, Li J, Liu C, Chen Z, et al
     CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
     J Gastroenterol Hepatol. 2022;37:1043-1051.
     PubMed     Abstract available
     
     
     May 2022
145. DUNN W, Song X, Koestler D, Grdinovac K, et al
     Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
     J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
     PubMed     Abstract available
     
     
     
146. CHAN SL, Wong N, Lam WKJ, Kuang M, et al
     Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives.
     J Gastroenterol Hepatol. 2022 May 15. doi: 10.1111/jgh.15889.
     PubMed     Abstract available
     
     
     
147. TENG PC, Agopian VG, Lin TY, You S, et al
     Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
     PubMed     Abstract available
     
     
     
148. CHOI AY, Kolb J, Shah S, Chahine A, et al
     Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.
     J Gastroenterol Hepatol. 2022 May 5. doi: 10.1111/jgh.15875.
     PubMed     Abstract available
     
     
     
149. WANG X, Gao X, Wu R, Chi X, et al
     Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
     J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
     PubMed     Abstract available
     
     
     April 2022
150. SHINKAI K, Sakamori R, Yamada R, Tahata Y, et al
     Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
     J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15853.
     PubMed     Abstract available
     
     
     
151. SATO M, Kobayashi T, Soroida Y, Tanaka T, et al
     Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images.
     J Gastroenterol Hepatol. 2022;37:678-684.
     PubMed     Abstract available
     
     
     
152. SASAKI Y, Abe Y, Nishise S, Yagi M, et al
     Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers.
     J Gastroenterol Hepatol. 2022;37:660-668.
     PubMed     Abstract available
     
     
     March 2022
153. LEUNG HH, Puspanathan P, Chan AW, Mustapha NRN, et al
     Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.
     J Gastroenterol Hepatol. 2022 Mar 31. doi: 10.1111/jgh.15843.
     PubMed     Abstract available
     
     
     
154. HUANG X, Zhu L, Wang L, Huang W, et al
     YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
     J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15816.
     PubMed     Abstract available
     
     
     
155. OGAWA Y, Nakahara T, Ono M, Kawaguchi T, et al
     Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.
     J Gastroenterol Hepatol. 2022;37:592-599.
     PubMed     Abstract available
     
     
     
156. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
     Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
     J Gastroenterol Hepatol. 2022;37:455-463.
     PubMed     Abstract available
     
     
     
157. YANG W, Yusufu Y, Wang C
     Gastrointestinal: A rare case of upper gastrointestinal bleeding: Splenosis mimicking gastric varices.
     J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15795.
     PubMed    
     
     
     February 2022
158. LIU Y, Liu S, Huang J, Zhu Y, et al
     Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.
     J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15799.
     PubMed     Abstract available
     
     
     
159. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
     Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
     J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
     PubMed     Abstract available
     
     
     
160. KEMP W, Clayton-Chubb D, Majeed A, Glenister KM, et al
     Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
     J Gastroenterol Hepatol. 2022;37:395-403.
     PubMed     Abstract available
     
     
     
161. BE KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, et al
     Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy.
     J Gastroenterol Hepatol. 2022;37:281.
     PubMed    
     
     
     January 2022
162. YUAN BH, Li RH, Huo RR, Li MJ, et al
     Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
     J Gastroenterol Hepatol. 2022 Jan 26. doi: 10.1111/jgh.15783.
     PubMed     Abstract available
     
     
     
163. CHAN WK, Tan SS, Chan SP, Lee YY, et al
     The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.
     J Gastroenterol Hepatol. 2022 Jan 25. doi: 10.1111/jgh.15787.
     PubMed     Abstract available
     
     
     
164. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
     Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
     J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
     PubMed     Abstract available
     
     
     
165. YU J
     The functional role and translational potential of gut microbiota and microbial metabolites in liver diseases.
     J Gastroenterol Hepatol. 2022;37:5-6.
     PubMed    
     
     
     
166. LI M, Rajani C, Zheng X, Jia W, et al
     The microbial metabolome in metabolic-associated fatty liver disease.
     J Gastroenterol Hepatol. 2022;37:15-23.
     PubMed     Abstract available
     
     
     
167. SUK KT, Koh H
     New perspective on fecal microbiota transplantation in liver diseases.
     J Gastroenterol Hepatol. 2022;37:24-33.
     PubMed     Abstract available
     
     
     
168. PAN Y, Zhang X
     Diet and gut microbiome in fatty liver and its associated liver cancer.
     J Gastroenterol Hepatol. 2022;37:7-14.
     PubMed     Abstract available
     
     
     December 2021
169. AHN HS, Kim HJ, Kang TU, Park SM, et al
     Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15759.
     PubMed     Abstract available
     
     
     
170. KERR CJ, Waterworth SP, Brodie D, Sandercock GRH, et al
     The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:3508-3514.
     PubMed     Abstract available
     
     
     
171. PAN J, Cen L, Zhou T, Yu M, et al
     Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:3438-3447.
     PubMed     Abstract available
     
     
     
172. HUANG H, Hou J, Liu K, Liu Q, et al
     RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
     J Gastroenterol Hepatol. 2021;36:3429-3437.
     PubMed     Abstract available
     
     
     
173. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
     Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
     J Gastroenterol Hepatol. 2021;36:3418-3428.
     PubMed     Abstract available
     
     
     
174. ZHU Z, Yin J, Dawsey SM, Liu B, et al
     Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.
     J Gastroenterol Hepatol. 2021;36:3410-3417.
     PubMed     Abstract available
     
     
     November 2021
175. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
     Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
     J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
     PubMed    
     
     
     
176. KIM BH, Yu SJ, Kang W, Cho SB, et al
     Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
     PubMed     Abstract available
     
     
     
177. POTOUPNI V, Georgiadou M, Chatzigriva E, Polychronidou G, et al
     Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
     J Gastroenterol Hepatol. 2021;36:3002-3014.
     PubMed     Abstract available
     
     
     
178. LEE S, Kim KW, Lee J, Park T, et al
     Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.
     J Gastroenterol Hepatol. 2021;36:3212-3218.
     PubMed     Abstract available
     
     
     
179. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
     Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:3204-3211.
     PubMed     Abstract available
     
     
     October 2021
180. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
     THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
     J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
     PubMed     Abstract available
     
     
     
181. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
     The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
     J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
     PubMed     Abstract available
     
     
     
182. NAKATSU G
     Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
     PubMed     Abstract available
     
     
     
183. CHEN T, Zhou K, Sun T, Sang C, et al
     Bile acid glycine:taurine ratios predict the progression of chronic liver disease.
     J Gastroenterol Hepatol. 2021 Oct 16. doi: 10.1111/jgh.15709.
     PubMed     Abstract available
     
     
     
184. HUO TI, Ho SY, Liao JI
     Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
     J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
     PubMed    
     
     
     
185. YIM HJ, Kim W, Ahn SH, Jung YK, et al
     Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
     J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
     PubMed     Abstract available
     
     
     
186. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
     Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
     J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
     PubMed     Abstract available
     
     
     
187. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
     Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
     J Gastroenterol Hepatol. 2021;36:2960-2966.
     PubMed     Abstract available
     
     
     
188. CHEN TP, Lin WY, Chiang CH, Shen TH, et al
     Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.
     J Gastroenterol Hepatol. 2021;36:2903-2910.
     PubMed     Abstract available
     
     
     
189. HU HT, Wang W, Chen LD, Ruan SM, et al
     Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound.
     J Gastroenterol Hepatol. 2021;36:2875-2883.
     PubMed     Abstract available
     
     
     
190. RODRIGUEZ-ANTONIO I, Lopez-Sanchez GN, Uribe M, Chavez-Tapia NC, et al
     Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:2720-2727.
     PubMed     Abstract available
     
     
     
191. WANG Y, Liu Y
     Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.
     J Gastroenterol Hepatol. 2021;36:2706-2714.
     PubMed     Abstract available
     
     
     September 2021
192. LI R, Ong Q, Wong CC, Chu ES, et al
     O-GlcNAcylation inhibits hepatic stellate cell activation.
     J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
     PubMed     Abstract available
     
     
     
193. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
     All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
     J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
     PubMed     Abstract available
     
     
     
194. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
     Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
     J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
     PubMed    
     
     
     
195. PENNISI G, Di Marco V, Buscemi C, Mazzola G, et al
     Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
     J Gastroenterol Hepatol. 2021;36:2389-2396.
     PubMed     Abstract available
     
     
     
196. CHEN D, Zeng R, Teng G, Cai C, et al
     Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.
     J Gastroenterol Hepatol. 2021;36:2619-2627.
     PubMed     Abstract available
     
     
     August 2021
197. ZHAO D, Xia L, Geng W, Xu D, et al
     Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
     J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
     PubMed     Abstract available
     
     
     
198. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
     Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
     J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
     PubMed     Abstract available
     
     
     
199. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
     Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
     J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
     PubMed     Abstract available
     
     
     
200. UENO M, Mano T, Kayahara T, Mizuno M, et al
     Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
     J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
     PubMed    
     
     
     
201. CHEN M, Hu G, Zhou X, Peng Z, et al
     Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
     PubMed     Abstract available
     
     
     
202. TAHER MK, Crispo JAG, Fortin Y, Moog R, et al
     Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
     J Gastroenterol Hepatol. 2021;36:2307-2314.
     PubMed     Abstract available
     
     
     
203. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
     Too little, too late: Palliation and end-stage liver disease.
     J Gastroenterol Hepatol. 2021;36:2303-2306.
     PubMed     Abstract available
     
     
     July 2021
204. MAK J, Chan SM, Siu B, Lai J, et al
     Hepatobiliary and Pancreatic: A tree in the liver.
     J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
     PubMed    
     
     
     
205. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
     Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
     J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
     PubMed     Abstract available
     
     
     
206. SHI M, Sheng L, Lian M, Miao Q, et al
     Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
     J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
     PubMed     Abstract available
     
     
     
207. WU L, Huang XQ, Li N, Xie C, et al
     An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
     J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
     PubMed     Abstract available
     
     
     
208. KRIGE J, Jonas E, Spence R, Bernon M, et al
     Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
     J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
     PubMed    
     
     
     
209. ITO T, Hanafusa N, Soneda N, Isoai A, et al
     Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
     J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
     PubMed     Abstract available
     
     
     
210. LIU CH, Ampuero J, Pavlides M, Wong VW, et al
     Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2021;36:1754-1768.
     PubMed     Abstract available
     
     
     
211. KANG HT, Jang K, Jun DW, Yoon EL, et al
     Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
     J Gastroenterol Hepatol. 2021;36:1997-2007.
     PubMed     Abstract available
     
     
     
212. KULKARNI AV, Anand L, Vyas AK, Premkumar M, et al
     Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial.
     J Gastroenterol Hepatol. 2021;36:1953-1961.
     PubMed     Abstract available
     
     
     
213. NISHIKAWA M, Kinoshita M, Morimoto Y, Ishikiriyama T, et al
     Lipopolysaccharide preconditioning reduces liver metastasis of Colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver.
     J Gastroenterol Hepatol. 2021;36:1889-1898.
     PubMed     Abstract available
     
     
     
214. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
     The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
     J Gastroenterol Hepatol. 2021;36:1971-1978.
     PubMed     Abstract available
     
     
     June 2021
215. COUPER MR, Chennapragada M, Magoffin A
     Hepatobiliary and Pancreatic: A rare peribiliary lesion.
     J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
     PubMed    
     
     
     
216. ZULLO A, Soncini M, Bucci C, Marmo R, et al
     Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
     J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
     PubMed     Abstract available
     
     
     
217. HO SY, Liu PH, Hsu CY, Ko CC, et al
     Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
     J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
     PubMed     Abstract available
     
     
     
218. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
     Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
     PubMed     Abstract available
     
     
     
219. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
     We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
     J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
     PubMed    
     
     
     
220. CHUN HS, Lee JS, Lee HW, Kim BK, et al
     Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
     J Gastroenterol Hepatol. 2021;36:1703-1713.
     PubMed     Abstract available
     
     
     
221. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
     Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2021;36:1470-1478.
     PubMed     Abstract available
     
     
     
222. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
     A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
     J Gastroenterol Hepatol. 2021;36:1497-1507.
     PubMed     Abstract available
     
     
     
223. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
     Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
     J Gastroenterol Hepatol. 2021;36:1435-1449.
     PubMed     Abstract available
     
     
     
224. LV T, Chen S, Li M, Zhang D, et al
     Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2021;36:1423-1434.
     PubMed     Abstract available
     
     
     
225. LIU D, Shen Y, Zhang R, Xun J, et al
     Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
     J Gastroenterol Hepatol. 2021;36:1670-1678.
     PubMed     Abstract available
     
     
     
226. HUANG Y, Huang F, Yang L, Hu W, et al
     Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
     J Gastroenterol Hepatol. 2021;36:1562-1570.
     PubMed     Abstract available
     
     
     
227. YIP TC, Wong VW, Wong GL
     Liver-heart connection in diabetes mellitus.
     J Gastroenterol Hepatol. 2021;36:1385-1386.
     PubMed    
     
     
     May 2021
228. ZHOU J, Wang C, Chen Z
     Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
     J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
     PubMed    
     
     
     
229. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
     Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
     J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
     PubMed     Abstract available
     
     
     
230. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
     Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
     J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
     PubMed     Abstract available
     
     
     
231. MA HL, Chen SD, Zheng KI, Yu Y, et al
     The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
     PubMed     Abstract available
     
     
     
232. TAK KY, Jang B, Lee SK, Nam HC, et al
     The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
     J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
     PubMed     Abstract available
     
     
     
233. ZHAO JA, Nie W, Dong L, Liu W, et al
     A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
     J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
     PubMed     Abstract available
     
     
     
234. CHANG H, Li J, Luo Y, Wu B, et al
     TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
     J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
     PubMed     Abstract available
     
     
     
235. YANG C, Liu J, Shi Q, Huang S, et al
     Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
     J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
     PubMed     Abstract available
     
     
     
236. XIE JM, Liu JH, Sun YH, Li W, et al
     Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
     J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
     PubMed    
     
     
     
237. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
     Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
     J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
     PubMed     Abstract available
     
     
     
238. CHEN Z, Jiang H, Wang Y, Liang R, et al
     Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
     PubMed     Abstract available
     
     
     
239. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
     FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
     J Gastroenterol Hepatol. 2021;36:1309-1316.
     PubMed     Abstract available
     
     
     
240. LI X, Qin P, Cao L, Lou Y, et al
     Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
     J Gastroenterol Hepatol. 2021;36:1326-1333.
     PubMed     Abstract available
     
     
     
241. TANDON R, Froghi S
     Artificial liver support systems.
     J Gastroenterol Hepatol. 2021;36:1164-1179.
     PubMed     Abstract available
     
     
     April 2021
242. PUDIPEDDI A, Han J, Leong R
     Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
     J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
     PubMed    
     
     
     
243. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
     Roadmap to resuming care for liver diseases after coronavirus disease-2019.
     J Gastroenterol Hepatol. 2021;36:885-892.
     PubMed     Abstract available
     
     
     
244. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
     The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:893-909.
     PubMed     Abstract available
     
     
     
245. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
     Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
     J Gastroenterol Hepatol. 2021;36:1006-1014.
     PubMed     Abstract available
     
     
     March 2021
246. SUNG YS, Park B, Park HJ, Lee SS, et al
     Radiomics and deep learning in liver diseases.
     J Gastroenterol Hepatol. 2021;36:561-568.
     PubMed     Abstract available
     
     
     
247. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
     Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
     J Gastroenterol Hepatol. 2021;36:543-550.
     PubMed     Abstract available
     
     
     
248. LEE HW, Sung JJY, Ahn SH
     Artificial intelligence in liver disease.
     J Gastroenterol Hepatol. 2021;36:539-542.
     PubMed     Abstract available
     
     
     February 2021
249. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
     Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:311-319.
     PubMed     Abstract available
     
     
     January 2021
250. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
     A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
     J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
     PubMed     Abstract available
     
     
     
251. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
     Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
     J Gastroenterol Hepatol. 2021;36:257-261.
     PubMed     Abstract available
     
     
     
252. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
     Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
     J Gastroenterol Hepatol. 2021;36:240-248.
     PubMed     Abstract available
     
     
     October 2020
253. YANG J, Sontag D, Gong Y, Minuk GY, et al
     Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
     J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
     PubMed     Abstract available
     
     
     September 2020
254. PYO JH, Kim TJ, Lee H, Choi SC, et al
     Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
     J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
     PubMed     Abstract available
     
     
     August 2020
255. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
     Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
     J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
     PubMed     Abstract available
     
     
     July 2020
256. KIM KS, Kwon HM, Jung KW, Sang BH, et al
     Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
     J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.